Medpace (NASDAQ:MEDP) CEO Sells 15,609 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,609 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.47, for a total transaction of $9,466,390.23. Following the completion of the sale, the chief executive officer directly owned 588,369 shares in the company, valued at approximately $356,828,147.43. This represents a 2.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Medpace Trading Up 1.3%

NASDAQ:MEDP traded up $8.11 during trading hours on Friday, hitting $620.75. 225,439 shares of the company were exchanged, compared to its average volume of 347,887. The stock has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company has a fifty day simple moving average of $547.09 and a 200 day simple moving average of $491.80.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the business earned $3.10 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MEDP. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. TD Cowen boosted their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Finally, Royal Bank Of Canada lifted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $584.18.

Institutional Investors Weigh In On Medpace

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Medpace in the second quarter worth approximately $1,323,047,000. AQR Capital Management LLC boosted its holdings in shares of Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP grew its position in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. Geode Capital Management LLC grew its position in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.